新型自由基清除剂依达拉奉对急性脑梗死的治疗作用

目的观察依达拉奉(MCI-186)治疗急性脑梗死的疗效和安全性.方法83例急性脑梗死病人随机分为治疗组和对照组.对照组按急性脑梗死常规方法治疗,治疗组在常规治疗基础上加用依达拉奉治疗.两组病例于治疗前、治疗后1个月分别进行巴氏指数(BI)及神经功能缺损量表(CSS)评定,并观察脑水肿程度改变及依达拉奉治疗期间的不良反应.结果两组治疗后1个月CSS和BI评分均有所改善,但治疗组明显优于对照组(P＜0.01),治疗组2周时中重度(等级为2～3)脑水肿发生率为12%,明显低于对照组31%(P＜0.05).依达拉奉治疗期间无明显副作用发生.结论依达拉奉治疗急性脑梗死是安全有效的.

Effects of a novel free radical scavenger edaravone on acute cerebral infarction

Objective To observe the efficacy and safety of edaravone in treatment of acute ischemic stroke. Methods A total of 83 patients of acute ischemic stroke were randomly divided and assigned to a therapy group and a control group. The control group was given a routine treatment of acute ischemic stroke. The therapy group was treated with edaravone in addition to the routine treatment received by the control group. Barthel index (BI) and Chinese stroke scale (CSS) in the two groups were assessed at different time points before treatment and 1 month after treatment. The changes of brain edema and the adverse reaction associated with the edaravone treatment were also observed. Results The results of CSS and BI of two groups improved after 1-month treatment, and CSS and BI of the therapy group was better than the control group (P<0.01). After 2-week treatment, the incidence of 2- and 3-grade brain edema of the therapy group was 12%, lower than that of the control group (31%) (P<0.05). There was no obvious adverse reaction of the edaravone treatment. Conclusion It is safe and effective to use edaravone in treatment of acute ischemic stroke.